Circulation. 2014;130:e199 267. S1.3-2. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_ Manual_for_ACC_AHA_Writing_Committees.pdf and http:// professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/ 2018. S1.3-3. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2015;133:1426 28. S1.3-4. Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical prac- tice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:268 310. 4.1.1. Selecting an Anticoagulant Regimen Balancing Risks and Benefits (Modified From Section 4.1.1. Selecting an Antithrombotic Regimen Balancing Risks and Benefits in the 2014 AF Guideline) S4.1.1-1. Di Biase L. Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. J Am Heart Assoc. 2016;5:e002776. S4.1.1-2. Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of dabi- gatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016;134:589 98. S4.1.1-3. Pan K-L, Singer DE, Ovbiagele B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta- analysis. J Am Heart Assoc. 2017;6:e005835. S4.1.1-4. Floyd CN, Ferro A. Indications for anticoagulant and antiplatelet combined therapy. BMJ. 2017;359:j3782. S4.1.1-5. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratifica- tion for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263 72. S4.1.1-6. Olesen JB, Torp-Pedersen C, Hansen ML, et al. 